Please assess the completion status of the following clinical trial:

Trial Title: Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Females; 18 years of age or greater~* Histologically proven invasive breast cancer~* American Joint Committee on Cancer (AJCC) clinical stage IIA - IIIB~* Tumor size greater than 10 millimeters~* HER2 positive~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Estrogen receptor (ER) positive or negative~* Ejection fraction greater than or equal to lower limit of normal for the institution by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA)~* Less than or equal to Grade 1 neuropathy according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0~* Planned lumpectomy or mastectomy~* Eligible for radiation therapy~* No prior treatment for invasive breast cancer~* Adequate organ system function per protocol as determined within 7 days prior to first dose of study treatment~* Women of childbearing potential must have a negative pregnancy test within 7 days prior to the first dose of study treatment and must agree to use adequate contraception methods during study treatment and for a minimum of 6 months following trastuzumab discontinuation~* Female subjects who are lactating should discontinue nursing prior to the first dose of study treatment and should refrain from nursing throughout the treatment period~Exclusion Criteria:~* Fine needle cytology only without other histologic evidence of invasive breast cancer~* Inflammatory breast cancer~* AJCC clinical stage T1a-b breast cancer (primary tumor less than or equal to 10 millimeters)~* Evidence of metastatic disease~* HER2 negative~* Ejection fraction less than lower limit of normal for the institution by ECHO or MUGA~* Corrected QT interval greater than 480 milliseconds~* Pre-existing cardiac dysfunction~* Prior history of invasive cancer within the past 3 years~* Synchronous bilateral breast cancer~* Pre-existing CTCAE v4.0 Grade 2 or greater neuropathy~* Hypersensitivity to halichondrin B or halichondrin B chemical derivative~* History of severe allergic reactions to cisplatin or other platinum containing compounds, or mannitol~* Mild, moderate, or severe hepatic impairment~* Moderate or severe renal impairment~* Hypokalemia or hypomagnesemia if it cannot be corrected prior to the first dose of study treatment~* Organ allografts requiring immunosuppression~* Known positive human immunodeficiency virus (HIV) status~* Prior major surgery within 28 days prior to the first dose of study treatment and/or presence of any non-healing wound, fracture, or ulcer~* Minor surgery or radiation therapy within 14 days prior to the first dose of study treatment~* Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eribulin, carboplatin, and trastuzumab (Type: EXPERIMENTAL): During Phase I, the eribulin dose will be assigned upon study enrollment. The maximum tolerated dose (MTD) determined in Phase I will be the dose used for Phase II. Eribulin will be administered intravenously (IV) over 2 to 5 minutes on Days 1 and 8 of each cycle. Carboplatin area under the curve (AUC) 6 will be administered IV over 15 to 30 minutes on Day 1 of each cycle. Trastuzumab will be administered as an IV infusion on Day 1 of each cycle. A loading dose of 8 mg/kg of trastuzumab will be administered over 90 minutes on Cycle 1 Day 1. Then, a maintenance dose of 6 mg/kg of trastuzumab will be administered over 30 to 90 minutes on Day 1 of Cycles 2 - 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).